Retrophin to buy Orphan Tech for $90M upfront

Retrophin to buy Orphan Tech for $90M upfront

Source: 
Seeking Alpha
snippet: 

Retrophin (NASDAQ:RTRX) has agreed to acquire privately-held Orphan Technologies and add OT-58, a novel enzyme replacement therapy in Phase 1/2 trial for the treatment of classical homocystinuria (HCU), a rare metabolic disorder characterized by elevated levels of plasma homocysteine that can lead to life-threatening thrombotic events.